Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAX 40279

Next Previous
Drug Profile

MAX 40279

Alternative Names: Max 4; MAX-40279; MAX-40279-001; MAX-40279-01; Max-5; Max-6; Multi-target tyrosine kinase inhibitor - Maxinovel

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Maxinovel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Hematopoietic progenitor kinase 1 inhibitors; Janus kinase inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 11 Apr 2023 Maxinovel plans a phase I trial in Idiopathic pulmonary fibrosis in 2023 (Maxinovel Pharmaceuticals pipeline, April 2023)
  • 11 Apr 2023 Maxinovel plans a phase II trial in Acute myeloid leukaemia in 2023 (Maxinovel Pharmaceuticals pipeline, April 2023)
  • 11 Apr 2023 Maxinovel plans a phase II trial in Idiopathic pulmonary fibrosis in 2024 (Maxinovel Pharmaceuticals pipeline, April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top